<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Absci Corp — News on 6ix</title>
    <link>https://6ix.com/company/absci-corp</link>
    <description>Latest news and press releases for Absci Corp on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 23 Apr 2026 20:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/absci-corp" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835417878dffbe2df0e0df3.webp</url>
      <title>Absci Corp</title>
      <link>https://6ix.com/company/absci-corp</link>
    </image>
    <item>
      <title>Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026</title>
      <link>https://6ix.com/company/absci-corp/news/absci-to-report-business-updates-and-first-quarter-2026-financial-and-operating-results-on-may-7-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-to-report-business-updates-and-first-quarter-2026-financial-and-operating-results-on-may-7-2026</guid>
      <pubDate>Thu, 23 Apr 2026 20:05:00 GMT</pubDate>
      <description>VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the first quarter 2026 after market close on Thursday, May 7, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to d</description>
    </item>
    <item>
      <title>Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference</title>
      <link>https://6ix.com/company/absci-corp/news/absci-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</guid>
      <pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
      <description>VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing</description>
    </item>
    <item>
      <title>Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic</title>
      <link>https://6ix.com/company/absci-corp/news/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-launches-abs-201-endometriosis-advisory-board-with-leading-experts-from-yale-ucsf-duke-and-the-mayo-clinic</guid>
      <pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
      <description>Experts at the forefront of reproductive medicine, fertility, and translational research will guide the clinical research program for a new therapeutic</description>
    </item>
    <item>
      <title>Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results</title>
      <link>https://6ix.com/company/absci-corp/news/absci-reports-business-updates-and-fourth-quarter-and-full-year-2025-financial-and-operating-results</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-reports-business-updates-and-fourth-quarter-and-full-year-2025-financial-and-operating-results</guid>
      <pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
      <description>Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex</description>
    </item>
    <item>
      <title>Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer</title>
      <link>https://6ix.com/company/absci-corp/news/absci-strengthens-clinical-leadership-with-appointment-of-ransi-somaratne-md-facc-mba-as-chief-medical-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-strengthens-clinical-leadership-with-appointment-of-ransi-somaratne-md-facc-mba-as-chief-medical-officer</guid>
      <pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
      <description>Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to</description>
    </item>
    <item>
      <title>Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026</title>
      <link>https://6ix.com/company/absci-corp/news/absci-to-report-business-updates-and-fourth-quarter-and-full-year-2025-financial-and-operating-results-on-march-24-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-to-report-business-updates-and-fourth-quarter-and-full-year-2025-financial-and-operating-results-on-march-24-2026</guid>
      <pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
      <description>VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing</description>
    </item>
    <item>
      <title>Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/absci-corp/news/absci-participate-44th-annual-jp-morgan-healthcare-conference-2025-12-16</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-participate-44th-annual-jp-morgan-healthcare-conference-2025-12-16</guid>
      <pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
      <description>VANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing</description>
    </item>
    <item>
      <title>Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization</title>
      <link>https://6ix.com/company/absci-corp/news/absci-reports-new-human-ex-vivo-data-demonstrating-abs-201tm-stimulates-hair-growth</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-reports-new-human-ex-vivo-data-demonstrating-abs-201tm-stimulates-hair-growth</guid>
      <pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
      <description>Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate</description>
    </item>
    <item>
      <title>Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research</title>
      <link>https://6ix.com/company/absci-corp/news/absci-and-us-soccer-legend-landon-donovan-partner-champion-patient-voice-hair-loss</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-and-us-soccer-legend-landon-donovan-partner-champion-patient-voice-hair-loss</guid>
      <pubDate>Wed, 10 Dec 2025 05:00:00 GMT</pubDate>
      <description>Partnership aims to destigmatize androgenetic alopecia and highlight the need for new therapeutic options that address the root cause of disease Donovan to</description>
    </item>
    <item>
      <title>Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia</title>
      <link>https://6ix.com/company/absci-corp/news/absci-announces-first-participants-dosed-phase-1-2a-headlinetm-trial-ai-designed</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-announces-first-participants-dosed-phase-1-2a-headlinetm-trial-ai-designed</guid>
      <pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
      <description>Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational</description>
    </item>
    <item>
      <title>Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results</title>
      <link>https://6ix.com/company/absci-corp/news/absci-reports-business-updates-and-third-quarter-2025-financial-and-operating-results</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-reports-business-updates-and-third-quarter-2025-financial-and-operating-results</guid>
      <pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
      <description>Reported interim results for Phase 1 trial for ABS-101 (anti-TL1A) On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in</description>
    </item>
    <item>
      <title>Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025</title>
      <link>https://6ix.com/company/absci-corp/news/absci-report-business-updates-and-third-quarter-2025-financial-and-operating-results</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-report-business-updates-and-third-quarter-2025-financial-and-operating-results</guid>
      <pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
      <description>VANCOUVER, Wash. and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics</description>
    </item>
    <item>
      <title>Absci to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/absci-corp/news/absci-participate-upcoming-investor-conferences-2025-10-27</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-participate-upcoming-investor-conferences-2025-10-27</guid>
      <pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
      <description>VANCOUVER, Wash. and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough</description>
    </item>
    <item>
      <title>Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial</title>
      <link>https://6ix.com/company/absci-corp/news/absci-host-kol-seminar-abs-201-androgenetic-alopecia-program-december-11-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-host-kol-seminar-abs-201-androgenetic-alopecia-program-december-11-2025</guid>
      <pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
      <description>Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership Phase 1/2a trial now expected to begin in December</description>
    </item>
    <item>
      <title>Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD</title>
      <link>https://6ix.com/company/absci-corp/news/absci-accelerates-ai-driven-drug-discovery-oracle-and-amd-2025-09-11</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-accelerates-ai-driven-drug-discovery-oracle-and-amd-2025-09-11</guid>
      <pubDate>Thu, 11 Sep 2025 04:00:00 GMT</pubDate>
      <description>Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs AUSTIN,</description>
    </item>
    <item>
      <title>Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg</title>
      <link>https://6ix.com/company/absci-corp/news/absci-expands-abs-201-scientific-advisory-board-addition-leading-dermatology-experts</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-expands-abs-201-scientific-advisory-board-addition-leading-dermatology-experts</guid>
      <pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
      <description>World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic</description>
    </item>
    <item>
      <title>Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results</title>
      <link>https://6ix.com/company/absci-corp/news/absci-reports-business-updates-and-second-quarter-2025-financial-and-operating</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-reports-business-updates-and-second-quarter-2025-financial-and-operating</guid>
      <pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
      <description>Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient</description>
    </item>
    <item>
      <title>Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target</title>
      <link>https://6ix.com/company/absci-corp/news/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-second-dermatology</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-second-dermatology</guid>
      <pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
      <description>Almirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci’s successful de novo molecule design for</description>
    </item>
    <item>
      <title>Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025</title>
      <link>https://6ix.com/company/absci-corp/news/absci-report-business-updates-and-second-quarter-2025-financial-and-operating-results</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-report-business-updates-and-second-quarter-2025-financial-and-operating-results</guid>
      <pubDate>Wed, 30 Jul 2025 04:00:00 GMT</pubDate>
      <description>VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing</description>
    </item>
    <item>
      <title>Absci Announces Pricing of Public Offering of Common Stock</title>
      <link>https://6ix.com/company/absci-corp/news/absci-announces-pricing-public-offering-common-stock-2025-07-24</link>
      <guid isPermaLink="true">https://6ix.com/company/absci-corp/news/absci-announces-pricing-public-offering-common-stock-2025-07-24</guid>
      <pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
      <description>VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential</description>
    </item>
  </channel>
</rss>